WHINURS HPV GENOTYPE PREVALENCE IN AUSTRALIAN WOMEN PRE-VACCINATION: what differences might there be for indigenous women?
•Télécharger en tant que PPT, PDF•
1 j'aime•2,117 vues
26th International Papillomavirus Conference: Satellite Symposium Enhancing HPV Prevention among Indigenous Populations: International Perspectives on Health and Well-Being Montreal, Quebec July 5, 2010 Panel 1 , Researching the Burden of HPV Disease, Immunization, and Cervical Screening among Indigenous Populations.
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (19)
En vedette
En vedette (20)
Similaire à WHINURS HPV GENOTYPE PREVALENCE IN AUSTRALIAN WOMEN PRE-VACCINATION: what differences might there be for indigenous women?
Similaire à WHINURS HPV GENOTYPE PREVALENCE IN AUSTRALIAN WOMEN PRE-VACCINATION: what differences might there be for indigenous women? (20)
Plus de National Aboriginal Health Organization
Plus de National Aboriginal Health Organization (11)
Dernier
Dernier (20)
WHINURS HPV GENOTYPE PREVALENCE IN AUSTRALIAN WOMEN PRE-VACCINATION: what differences might there be for indigenous women?
- 1. WHINURS HPV GENOTYPE PREVALENCE IN AUSTRALIAN WOMEN PRE-VACCINATION: what differences might there be for indigenous women? Suzanne M. Garland, 1,2 Julia Brotherton, 3 Matthew Stevens, 1,2 John Condon, 4 Peter McIntyre, 5 David Smith, 6 & Sepehr Tabrizi 1,2 on behalf of the WHINURS Study Group. Director of Microbiological Research, Director of Clinical Microbiology and Infectious Diseases, 1, The Royal Women's Hospital, Professor, Department of Obstetrics, Gynaecology, University of Melbourne 2 Melbourne , Australia . Inaugural and Past President of AOGIN IPV Montreal 2010 Enhancing HPV Prevention among Indigenous Populations: International Perspectives on Health and Well-Being Symposium July 5 th
- 2. Australia cervical cancer Source: AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries) 2008. Cancer in Australia: an overview, 2008. Cancer series no. 46. Cat. no. CAN 42.Canberra: AIHW. 13.2 6.9 4.0 1.9 734 cancer cases in 2005, WSR 5.9 per 100,000 Approx 90,000 LSIL and 15,000 CIN2/3 diagnosed p.a.
- 4. Chlamydia by ATSI status, State/Territory and year Source: State/Territory health authorities Aboriginal and Torres Strait Islander Non-Indigenous
- 5. Gonorrhoea by ATSI status, State/Territory and year Source: State/Territory health authorities Aboriginal and Torres Strait Islander Non-Indigenous
- 6. Infectious syphilis by ATSI status, State/Territory & year Source: State/Territory health authorities Aboriginal and Torres Strait Islander Non-Indigenous
- 16. Laboratory m ethodology: HPV detection strategy HPV (-) PreservCyt Roche Amplicor In-house consensus HPV assay HPV DNA A mplifi cation Extraction on MagNA Pure LC DNA Sequencing using Beckman CEQ 8000 Negative Negative Positive Positive Negative HPV typing using Roche Linear Array HPV (+)
Notes de l'éditeur
- In 2006-07 total vaccine costs through NIP $283 million 1 The 2 nd application for the 4 year HPV vaccination program was initially estimated to cost $436 million (revised to nearly $500 million).
- Over all 75-80% of all eligible cohorts received Dose 1 Higher in younger (Yr 7-9) Lower in Yr 10-12 (data on next slide hidden if you want to show it) 96% of vaccinees returned for Dose 2 87 % completed the course
- We know that, by the end of June 2008 3.7 m doses of the vaccine have been distributed in Australia 1.9 m doses have been distributed to general practices Data from the first year of the school-based program (2007) is currently being collated and will be submitted for publication in Communicable Disease Intelligence later this year. Preliminary analysis suggests that, across jurisdictions and school years, completion of three doses ranged from 42% to 77% in 2007.. Both NSW and Victoria, the two largest States, achieved coverage of 70-75% in almost all year groups.
- Awareness of National HPV Vaccination Program is very high Several market research studies confirm: >90% of young women & >80% of parents are aware of Australia’s free HPV Vaccination Program for females 12 to 26 years old Uptake among 18-26 year olds: 2 year uptake target (45%) was exceeded in only 6 months estimated to be 65% to 70% by end 2008 1 and ~80% at June 30 2009 1
- This is an example of one country’s surveillance objectives following the introduction of a large HPV vaccination program targeting 12 year old girls in the first year of high school, with catch up to the age of 26. Australia has established a National HPV Vaccination Register which will measure vaccine coverage and will be linked in the future to cervical screening registry data to evaluate vaccine effectiveness. Australia has existing Pap test registries, cancer registries and vaccine safety surveillance. Australia uses conventional Pap testing and HPV typing is not routine. There is no pre-existing genital warts surveillance system or recurrent respiratory papillomatosis register.
- Brief background of HPV vaccination in Australia How best can measure vaccine effectiveness? WHINURS study Design and plan of the study Methodology (laboratory assays, quality assurance of the study} Progress and interim results Lessons learnt and challenges
- For WHINURS, all samples are tested by amplicor and positives typed by LA. Then all negatives are put through our in-house consensus PCR and all positives from that will be genotyped by LA. We will sequence all positive Amplicor/in house PCR which are negative by Linear Array. At the moment we only have about 25% positive by Amplicor and have not yet done the in-house assay, but would need to do this on the first 1500 samples. The list price of Amplicor is $40 and LA $100. We charge $64 for Amplicor and $180 for LA which includes other consumables and staff costs. The cost for our In house assay is $20Hope this is what you are after for prices.
- In women <30 there was no difference in the prevalence of HR HPV between non Indigenous and Indigenous women. However Indigenous women ≥ 30, whilst equally likely to have HPV 16/18 (vaccine types), were more likely to other HPV types detected, including other HR types